OncBioMune Pharmaceuticals, Inc.
Top 10 Reasons to Buy OBMP
1. Consolidation over the past week looks to be over, next move up on the charts starting. Full size chart
2. Lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer
3. A clinical stage biopharmaceutical company that develops cancer immunotherapy products
4. Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting
5. 9 of the 14 patients that have received 6 vaccines have had increased PSA doubling time, suggesting ProscaVax is slowing tumor growth.
6. Preparing to enter a Phase 2/3 trial in Mexico through a Joint Venture with its acquisition target and Mexican partner Vital Laboratorios S.A. de C.V
7. Departments of Urology and Oncology Approve Protocol for OncBioMune’s Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
8. Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology
9. Shares Outstanding 61,158,013 a/o Feb 24, 2017; Float 11,861,349 a/o Feb 24,2017
10. OTC QB SEC Reporting Current
Brought to you by: Blue Horseshoe Alerts
Sign up for our free newsletter